Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17167206 | 0.94 | EPHX2 (0.50) | EPHX2LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL17767811 | 0.87 | EPHX2 (0.61) | EPHX2LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL17767806 | 0.87 | EPHX2 (0.61) | EPHX2LMNAHTTMEN1ALDH1A1 | |
| SCHEMBL2944258 | 0.85 | LMNA (0.52) | EPHX2LMNASMN1; SMN2HTTALDH1A1 | |
| SCHEMBL29467720 | 0.84 | HTT (0.54) | EPHX2LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL19646416 | 0.83 | LMNA (0.52) | EPHX2LMNASMN1; SMN2HTTMEN1 | |
| SCHEMBL28090584 | 0.83 | EPHX2 (0.58) | EPHX2HTTMEN1ALDH1A1HPGD | |
| SCHEMBL14005200 | 0.83 | EPHX2 (0.58) | EPHX2HTTMEN1ALDH1A1HPGD | |
| SCHEMBL6014038 | 0.83 | HDAC3 (0.59) | EPHX2HTTMEN1ALDH1A1HPGD | |
| SCHEMBL28928287 | 0.83 | LMNA (0.54) | EPHX2LMNASMN1; SMN2HTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186603-B2 | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses | VICTORIA LINK LIMITED (NZ) | 2021-11-30 | — | — | US | disclosed |
| US-20200131217-A1 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMECEUTICAL USES | VICTORIA LINK LIMITED (NZ) | 2020-04-30 | — | — | US | disclosed |
| US-9879041-B2 | Saccharide dendritic cluster compounds as inhibitors of BACE-1 | VICTORIA LINK LIMITED (NZ) | 2018-01-30 | — | — | US | disclosed |
| US-9828341-B2 | Dendritic core compounds | VICTORIA LINK LIMITED (NZ) | 2017-11-28 | — | — | US | disclosed |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | UNIVERSITY OF LIVERPOOL (GB) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131217-A1 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMECEUTICAL USES | GBA1, UGCG, GBA2 | EPHX2 1372/4885LMNA 3765/4885SMN1; SMN2 1285/4885 |
| US-20170152279-A9 | Saccharide Dendritic Cluster Compounds as Inhibitors of Bace-1 | BACE1, BACE2, APP | EPHX2 1589/4885LMNA 3489/4885SMN1; SMN2 814/4885 |
| US-11186603-B2 | Heparan sulfate glycomimetic compounds and their pharmaceutical and cosmeceutical uses | GBA1, UGCG, GBA2 | EPHX2 1372/4885LMNA 3765/4885SMN1; SMN2 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.